Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AON-D21 in Severe Community-Acquired Pneumonia
NCT05962606Phase 2Completed
- Sponsor
- Aptarion Biotech
- Start
- Feb 2024
- Primary completion
- Mar 2026
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in community acquired pneumonia (CAP) comparing AON-D21 plus Standard of Care with Placebo plus Standard of Care (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 28 days. Started Feb 2024; status: completed.
02
Drugs
AON-D21
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT05962606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962606.